Pandion Therapeutics, Inc. (PAND) relating to its proposed acquisition by Merck. Under the terms of the agreement, PAND shareholders will receive $60.00 in cash per share.
Pandion Therapeutics, Inc. (PAND) relating to its proposed acquisition by Merck. Under the terms of the agreement, PAND shareholders will receive $60.00 in cash per share.